Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines for autoimmune and inflammatory diseases. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2026-05-08. The company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. The company also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development.
Forward revenue growth (NTM) 
